> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Celgene, IBM Watson Partner on New Pharmacovigilance Program
- URL: https://www.fdaweb.com/celgene-ibm-watson-partner-on-new-pharmacovigilance-program/
- Published: 2016-11-02T12:00:00.000Z
- Updated: 2026-09-14T21:44:29.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137244

Celgene and IBM Watson Health have decided to collaborate to co-develop a new program, IBM Watson for Patient Safety, that aims to enhance pharmacovigilance methods used to collect, assess, monitor, and report adverse drug reactions. The new offering will run on the Watson Health Cloud. “The collaboration will combine Watson’s cognitive computing ability with Celgene’s deep history and experience in drug safety and risk management in order to create an outcome- and evidence-based drug safety decision support system for life science companies,” an IBM Watson release says. “Watson’s cognitive computing engine continuously learns, so it is expected that Watson for Patient Safety will increasingly be able to help identify potential drug safety signals.”

Watson for Patient Safety is being developed to enable the rapid collection, collation and automated analysis of high volumes of data from diverse sources, including anonymized electronic medical records, medical claims databases and other healthcare information sources. It will be designed to “drive pharmaceutical companies’ understanding of complex safety questions, and delivery of evidence-based insights to help support ongoing understanding of the safety profiles of drug products by stakeholders. This advanced approach is intended to help biopharmaceutical companies and other stakeholders to better manage and interpret large volumes of Individual Case Safety Reports (ICSRs) describing potential side effects associated with drug products. Across the biopharmaceutical industry these reports are increasing in volume and complexity as data sources grow and regulations evolve.”

Watson for Patient Safety will be developed in phases, with the first module anticipated within the next year.